AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15058368 — intervention group
Group type: COMPARATOR
Intervention: Gracey conventional curettes
Number of subjects: 10
Study 10926345 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate combination therapy 50/250 microg twice daily
Number of subjects: 353
Study 10926345 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 800 microg twice daily
Number of subjects: 353
Study 8885957 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-saturated-fat, low-cholesterol diet
Number of subjects: 1062
Study 8885957 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted diet (Control)
Number of subjects: 1062
Study 1600111 — intervention group
Group type: EXPERIMENTAL
Intervention: Syrup formulations
Number of subjects: 40
Study 1600111 — intervention group
Group type: COMPARATOR
Intervention: Capsule formulations
Number of subjects: 40
Study 1600111 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosage forms
Number of subjects: 40
Study 6364770 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 0
Study 6364770 — intervention group
Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 0
Study 31398998 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfort scores
Number of subjects: 100
Study 31398998 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain scores
Number of subjects: 100
Study 28929919 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation therapy assisted walking (FES‐T)
Number of subjects: 34
Study 28929919 — intervention group
Group type: COMPARATOR
Intervention: Conventional aerobic and resistance training (CONV)
Number of subjects: 34
Study 25351866 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral parent training (BPT) accessed via the Internet
Number of subjects: 307
Study 24092833 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D₃ 4000 IU/d
Number of subjects: 323
Study 24092833 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 IU/d)
Number of subjects: 323
Study 24092833 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D₃ 400 IU/d
Number of subjects: 323
Study 24092833 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D₃ (all doses)
Number of subjects: 323
Study 21818647 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 60
Study 21818647 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 60
Study 19846212 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine vaginal wipes during active labour and full-body chlorhexidine washes at birth
Number of subjects: 8011
Study 19846212 — intervention group
Group type: COMPARATOR
Intervention: External genitalia water wipes during active labour and foot water washes at birth (Control)
Number of subjects: 8011
Study 16140508 — intervention group
Group type: EXPERIMENTAL
Intervention: One-Stage group (n=32) received 12 months of inpatient treatment
Number of subjects: 108
Study 16140508 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-Down group (n=29) received 6 months of inpatient treatment followed by 12 months of outpatient therapy
Number of subjects: 108
Study 16140508 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=47) used routinely available services
Number of subjects: 108
Study 14530727 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial surgical resection
Number of subjects: 98
Study 14530727 — intervention group
Group type: COMPARATOR
Intervention: Delayed resection after chemotherapy
Number of subjects: 98
Study 14530727 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial surgery
Number of subjects: 98
Study 14530727 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy followed by resection
Number of subjects: 98
Study 14530727 — intervention group
Group type: COMPARATOR
Intervention: Delayed operation excluding those who received only radiotherapy
Number of subjects: 98
Study 10720081 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (100 microg) alone
Number of subjects: 10
Study 10720081 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (100 microg) plus arginine (30 g)
Number of subjects: 10
Study 10720081 — intervention group
Group type: COMPARATOR
Intervention: GHRH (100 microg) plus saline
Number of subjects: 10
Study 10720081 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (100 microg) plus arginine
Number of subjects: 10
Study 9121089 — intervention group
Group type: EXPERIMENTAL
Intervention: betapressin (penbutolol) 40 mg
Number of subjects: 24
Study 9121089 — intervention group
Group type: COMPARATOR
Intervention: betapressin at a mean daily dose 108.4 +/- 6.25 mg
Number of subjects: 24
Study 1527367 — intervention group
Group type: COMPARATOR
Intervention: Room air breathing
Number of subjects: 12
Study 1527367 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% carbon dioxide gas mixture breathing
Number of subjects: 12
Study 1527367 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled hyperventilation
Number of subjects: 12
Study 3965820 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioplegic solution infused via the aortic root
Number of subjects: 68
Study 3965820 — intervention group
Group type: COMPARATOR
Intervention: Reinfusions of cardioplegic solution given both centrally and through the completed distal left anterior descending anastomosis
Number of subjects: 68
Study 30037301 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care
Number of subjects: 124
Study 30037301 — intervention group
Group type: COMPARATOR
Intervention: Institutional care
Number of subjects: 124
Study 30388751 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructooligosaccharides (FOS)
Number of subjects: 36
Study 30388751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 27555901 — intervention group
Group type: EXPERIMENTAL
Intervention: Locator bar attachment
Number of subjects: 16
Study 27555901 — intervention group
Group type: COMPARATOR
Intervention: Locator implant attachment
Number of subjects: 16
Study 27555901 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study 24975729 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection with bone marrow mesenchymal stem cells (BMSCs) after PCI
Number of subjects: 58
Study 24975729 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BMSC transplantation)
Number of subjects: 58
Study 21887732 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 62
Study 21887732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 19996066 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment to an average systolic blood pressure of 135 to 145 mm Hg and an average diastolic blood pressure of 60 to 90 mm Hg
Number of subjects: 2699
Study 19996066 — intervention group
Group type: COMPARATOR
Intervention: PAD patients
Number of subjects: 2699
Study 17603828 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based interactive asthma educational and monitoring program (Blue Angel for Asthma Kids)
Number of subjects: 164
Study 17603828 — intervention group
Group type: COMPARATOR
Intervention: Traditional asthma care plan (control group)
Number of subjects: 164
Study 16116628 — intervention group
Group type: EXPERIMENTAL
Intervention: ruboxistaurin (RBX) mesylate
Number of subjects: 205
Study 11147684 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamed femoral nailing
Number of subjects: 100
Study 11147684 — intervention group
Group type: COMPARATOR
Intervention: Unreamed femoral nailing
Number of subjects: 100
Study 9726382 — intervention group
Group type: EXPERIMENTAL
Intervention: Olsalazine sodium, 3 g/day
Number of subjects: 168
Study 9726382 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine, 3 g/day
Number of subjects: 168
Study 7973212 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by radiotherapy
Number of subjects: 240
Study 7973212 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 240
Study 2564233 — intervention group
Group type: EXPERIMENTAL
Intervention: MC903 cream (1.2 mg MC903 per g cream)
Number of subjects: 10
Study 2564233 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 10
Study 31044491 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose factor VIII (FVIII) tertiary prophylaxis, 10 IU/kg body weight, two times per week
Number of subjects: 50
Study 31044491 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose factor VIII (FVIII) tertiary prophylaxis
Number of subjects: 50
Study 31044491 — intervention group
Group type: COMPARATOR
Intervention: On-demand treatment
Number of subjects: 50
Study 29231349 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear point embedding (Fugugou, Gan, Pizhixia, Shenmen) 30 minutes before anesthesia induction, applied until the end of surgery
Number of subjects: 50
Study 29231349 — intervention group
Group type: COMPARATOR
Intervention: Control group received auricular tape applied at the same points without stimulation 30 minutes before anesthesia induction
Number of subjects: 50
Study 25474552 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinized saline (10 U ml(-1))
Number of subjects: 120
Study 25474552 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 120
Study 23076004 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMFs)
Number of subjects: 55
Study 23076004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 21245916 — intervention group
Group type: EXPERIMENTAL
Intervention: H58‐C clonal complex
Number of subjects: 267
Study 21245916 — intervention group
Group type: EXPERIMENTAL
Intervention: H58‐E2 haplotype
Number of subjects: 267
Study 21245916 — intervention group
Group type: EXPERIMENTAL
Intervention: H58‐C
Number of subjects: 267
Study 21245916 — intervention group
Group type: EXPERIMENTAL
Intervention: H58‐E2
Number of subjects: 267
Study 21245916 — intervention group
Group type: EXPERIMENTAL
Intervention: H58 S. Typhi
Number of subjects: 267
Study 21245916 — intervention group
Group type: EXPERIMENTAL
Intervention: IncHI1 plasmid‐bearing S. Typhi H58‐C
Number of subjects: 267
Study 18566548 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg
Number of subjects: 0
Study 18566548 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 0
Study 18566548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16822118 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills intervention
Number of subjects: 0
Study 16822118 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 12966367 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/d)
Number of subjects: 13
Study 12966367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 10852440 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH (50, 75, or 100 microg recombinant human PTH‐(1‐84))
Number of subjects: 66
Study 10852440 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg daily) after PTH treatment
Number of subjects: 66
Study 10852440 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH (highest dose)
Number of subjects: 66
Study 10852440 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH
Number of subjects: 66
Study 10852440 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 66
Study 9044492 — intervention group
Group type: COMPARATOR
Intervention: Group A (manikin training only)
Number of subjects: 52
Study 9044492 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (manikin and live patient training)
Number of subjects: 52
Study 7804523 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery
Number of subjects: 0
Study 7804523 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 2895577 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 10 to 40 mg
Number of subjects: 146
Study 2895577 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 25 to 100 mg
Number of subjects: 146
Study 31383029 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-led care for HLA Ab+ participants
Number of subjects: 0
Study 31383029 — intervention group
Group type: COMPARATOR
Intervention: Standard care for HLA Ab+ participants
Number of subjects: 0
Study 31383029 — intervention group
Group type: COMPARATOR
Intervention: HLA-Ab-unblinded group
Number of subjects: 0
Study 28408020 — intervention group
Group type: EXPERIMENTAL
Intervention: IABP‐SHOCK II risk score categories (low, intermediate, high)
Number of subjects: 137
Study 26615812 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia education module (6-minute interactive module)
Number of subjects: 50
Study 26615812 — intervention group
Group type: COMPARATOR
Intervention: Verbal discussion alone (Control)
Number of subjects: 50
Study 24097273 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.2 mg daily for 4 weeks followed by Tamsulosin 0.2 mg and Solifenacin 5.0 mg daily for 8 weeks (Group 1)
Number of subjects: 156
Study 24097273 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg and Solifenacin 5.0 mg combination for 12 weeks (Group 2)
Number of subjects: 156
Study 22320148 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 200 μg
Number of subjects: 561
Study 22320148 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 400 μg
Number of subjects: 561
Study 22320148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 561
Study 19448566 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 16
Study 19448566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17298965 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g/day propionyl‐L‐carnitine (PLC) for 7 days
Number of subjects: 25
Study 17298965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 17298965 — intervention group
Group type: COMPARATOR
Intervention: Control group (40 healthy individuals)
Number of subjects: 25
Study 15347710 — intervention group
Group type: EXPERIMENTAL
Intervention: Superimposed images from coronary angiography and gated myocardial perfusion SPECT (MPI)
Number of subjects: 0
Study 15347710 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D surface map generated from quantitative gated SPECT (QGS)/quantitative perfusion SPECT (QPS) program
Number of subjects: 0
Study 15347710 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined angiographic images and 3D surface map
Number of subjects: 0
Study 11884296 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (counseling for low-saturated fat, low-cholesterol diet)
Number of subjects: 1062
Study 11884296 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 1062
Study 9791844 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg Panax ginseng supplementation
Number of subjects: 28
Study 9791844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 8566629 — intervention group
Group type: EXPERIMENTAL
Intervention: Simethicone
Number of subjects: 86
Study 8566629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 2790865 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF/SnF2 toothpaste
Number of subjects: 92
Study 2790865 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF/SnF2 toothpaste plus AmF/SnF2 mouthwash
Number of subjects: 92
Study 2790865 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 92
Study 2790865 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste plus AmF/SnF2 mouthwash
Number of subjects: 92
Study 322273 — intervention group
Group type: EXPERIMENTAL
Intervention: Tragant sulfate (pepsin inhibitor)
Number of subjects: 0
Study 322273 — intervention group
Group type: EXPERIMENTAL
Intervention: Deglycyrrhizinized liquorice extract
Number of subjects: 0
Study 6947504 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin F2 alpha (PGF2 alpha)
Number of subjects: 9
Study 6947504 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 9
Study 31587091 — intervention group
Group type: EXPERIMENTAL
Intervention: autologous bone marrow-derived culture-expanded MSCs (n=16)
Number of subjects: 47
Study 31587091 — intervention group
Group type: EXPERIMENTAL
Intervention: autologous bone marrow-derived culture-expanded MSCs + PRP (n=14)
Number of subjects: 47
Study 31587091 — intervention group
Group type: COMPARATOR
Intervention: corticosteroid (n=17)
Number of subjects: 47
Study 31587091 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 47
Study 31623857 — intervention group
Group type: EXPERIMENTAL
Intervention: DL1 (trametinib 1.5 mg, GSK2141795 50 mg)
Number of subjects: 26
Study 31623857 — intervention group
Group type: EXPERIMENTAL
Intervention: DL-1 (trametinib 1.5 mg, GSK2141795 25 mg)
Number of subjects: 26
Study 29037544 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva pushing
Number of subjects: 80
Study 29037544 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous pushing
Number of subjects: 80
Study 26519230 — intervention group
Group type: EXPERIMENTAL
Intervention: Siponimod 2 mg
Number of subjects: 304
Study 26519230 — intervention group
Group type: EXPERIMENTAL
Intervention: Siponimod 10 mg
Number of subjects: 304
Study 26519230 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 304
Study 26519230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 23388502 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble maize fibre (SCF)
Number of subjects: 20
Study 23388502 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch (RS)
Number of subjects: 20
Study 23388502 — intervention group
Group type: EXPERIMENTAL
Intervention: SCF+P
Number of subjects: 20
Study 23388502 — intervention group
Group type: EXPERIMENTAL
Intervention: RS+P
Number of subjects: 20
Study 23388502 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin control
Number of subjects: 20
Study 21836102 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 days of bed rest (BR) in FDR subjects
Number of subjects: 13
Study 21836102 — intervention group
Group type: COMPARATOR
Intervention: 10 days of bed rest (BR) in control (CON) subjects
Number of subjects: 13
Study 19516032 — intervention group
Group type: COMPARATOR
Intervention: Short-term androgen suppression (6 months)
Number of subjects: 970
Study 19516032 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term androgen suppression (2.5 years)
Number of subjects: 970
Study 17570983 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelnidipine 16 mg once daily
Number of subjects: 30
Study 17570983 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg once daily
Number of subjects: 30
Study 15545306 — intervention group
Group type: EXPERIMENTAL
Intervention: DOV 216,303 at 150 mg (single dose)
Number of subjects: 13
Study 15545306 — intervention group
Group type: EXPERIMENTAL
Intervention: DOV 216,303 at 100 mg (multiple doses for 10 days)
Number of subjects: 13
Study 15545306 — intervention group
Group type: COMPARATOR
Intervention: DOV 216,303 (single and multiple doses)
Number of subjects: 13
Study 15545306 — intervention group
Group type: EXPERIMENTAL
Intervention: DOV 216,303 (doses > 10 mg)
Number of subjects: 13
Study 12177637 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressive treatment (mirtazapine, placebo-controlled); alternative treatment with citalopram if needed.
Number of subjects: 2140
Study 12177637 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (CAU); no treatment offered, psychiatric treatment outside the study recorded.
Number of subjects: 2140
Study 10090926 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin (CSA) alone
Number of subjects: 115
Study 10090926 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of horse antithymocyte globulin (ATG) and cyclosporin (CSA)
Number of subjects: 115
Study 8578271 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiverine 15 mg/d
Number of subjects: 185
Study 8578271 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiverine 30 mg/d
Number of subjects: 185
Study 8578271 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiverine 45 mg/d
Number of subjects: 185
Study 8578271 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiverine 60 mg/d
Number of subjects: 185
Study 8578271 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiverine (15, 30, 45, 60 mg/d)
Number of subjects: 185
Study 2084727 — intervention group
Group type: EXPERIMENTAL
Intervention: Homatropine hydrobromide (0.5% drops, two drops given twice spaced 15 minutes apart)
Number of subjects: 28
Study 2084727 — intervention group
Group type: COMPARATOR
Intervention: Placebo eyedrops
Number of subjects: 28
Study 2084727 — intervention group
Group type: EXPERIMENTAL
Intervention: Homatropine hydrobromide
Number of subjects: 28
Study 26519 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 40 mg (20 mg twice daily) increased to a maximum of 560 mg daily
Number of subjects: 30
Study 26519 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 30
Study 26519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31306184 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP4 (PEEP 4 cmH2O)
Number of subjects: 40
Study 31306184 — intervention group
Group type: COMPARATOR
Intervention: PEEP8 (PEEP 8 cmH2O)
Number of subjects: 40
Study 28577267 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training (CT)
Number of subjects: 39
Study 28577267 — intervention group
Group type: COMPARATOR
Intervention: Active music therapy (AMT)
Number of subjects: 39
Study 28577267 — intervention group
Group type: COMPARATOR
Intervention: Neuroeducation (NE)
Number of subjects: 39
Study 25636304 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (maximal dose 90 mg/day)
Number of subjects: 40
Study 25636304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23896810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 23896810 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age, shorter duration of illness, greater baseline symptom severity, shorter trial duration
Number of subjects: 50